Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q1 EPS of ($0.45), $0.16 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $1.57 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.